Elsevier

Drug and Alcohol Dependence

Volume 183, 1 February 2018, Pages 25-33
Drug and Alcohol Dependence

Full length article
Cannabis use disorder and male sex predict medical cannabis card status in a sample of high risk adolescents

https://doi.org/10.1016/j.drugalcdep.2017.11.007Get rights and content

Highlights

  • Adolescent cannabis use disorder and male sex predict medical cannabis (med) card.

  • Neither self-reported mental illness nor general health predicted med card status.

  • Young adults with med cards had higher rates concurrent cannabis use disorder.

  • High-risk adolescents have high participation in med card programs as young adults.

  • Suggests benefits of screening for substance use disorders in med card evaluations.

Abstract

Objective

To examine if a substance use disorder (SUD), especially cannabis use disorder in adolescence, predicts future medical cannabis card status among high-risk youth.

Methods

Data collection occurred in Denver and San Diego. We recruited adolescents, with or at high risk for SUD and conduct problems (hereafter probands) and their siblings (n = 654). Baseline (Wave 1) assessments took place between 1999 and 2008, and follow-up (Wave 2) took place between 2010 and 2013. In initial bivariate analyses, we examined whether baseline DSM-IV cannabis abuse/dependence (along with other potential predictors) was associated with possessing a medical cannabis card in young adulthood (Wave 2). Significant predictors were then included in a multiple binomial regression. Self-reported general physical health was also evaluated at both time points. Finally, within Wave 2, we tested whether card status was associated with concurrent substance dependence.

Results

About 16% of the sample self-reported having a medical cannabis card at follow-up. Though bivariate analyses demonstrated that multiple predictors were significantly associated with Wave 2 card status, in our multiple binomial regression only cannabis abuse/dependence and male sex remained significant. At Wave 2, those with a medical cannabis card were significantly more likely to endorse criteria for concurrent cannabis dependence. There was no significant difference in self-reported general physical health.

Conclusions

Cannabis abuse/dependence and male sex positively predicted future medical cannabis card holder status among a sample of high risk adolescents. Physicians conducting evaluations for medical cannabis cards should carefully evaluate and consider past and concurrent cannabis addiction.

Introduction

In recent decades, there has been a shift in the legal perspective in the United States regarding cannabis use. In 1996, California enacted the Compassionate Use Act, becoming the first state to legalize medical cannabis (People of the State of California, 1996). Many states followed suit, including Colorado with passage of Amendment 20 to the state constitution in 2000, and as of August 2017, 29 states and D.C. have medical cannabis laws (MMLs; ProCon, 2017). However, individuals in these states can still be charged for cannabis-related crimes under federal law because the Drug Enforcement Agency schedules cannabis as a Class I substance and because Federal law considers possession and distribution of cannabis a crime (USDEA, 2016). Between 2001 and 2008 medical cannabis participation was “relatively low and flat” (Fairman, 2016). But in 2009, the Department of Justice issued the Ogden Memorandum, which stopped the Federal prosecution of “individuals whose actions are in clear and unambiguous compliance with existing state laws providing for the medical use of cannabis” (Ogden, 2009). Starting in 2009, some states experienced rapid growth of their medical cannabis registries (Fairman, 2016, Schuermeyer et al., 2014). For example, in Colorado between 2001 and 2008 a total of only 6704 new patients applied for a medical cannabis card (The Colorado Medical Marijuana Registry, 2009). In 2009, Colorado saw a dramatic increase in the number of cardholders and by the end of 2010, 116,198 people held medical cannabis cards (The Colorado Medical Marijuana Registry, 2010). Unfortunately, some states do not release state registry data or do not require registration (e.g., California’s medical cannabis registry is voluntary; Bowles, 2012), making monitoring of prevalence of medical cannabis participation challenging. In 2012, Colorado legalized recreational cannabis use for adults, though the first recreational sales did not begin until January of 2014. As of August 2017, eight states, including California, have legalized recreational cannabis (NORML, 2016). Thus studying medical cannabis card status during years 2010–2013 in Colorado and California, as we do here, allows examining a period which comes after the issuance of the Ogden-Memo but is prior to the initiation of legal recreational cannabis sales in either state.

There has been keen interest in understanding whether this shifting legal landscape may lead to changes in cannabis use patterns and cannabis use disorder prevalence among adolescents and adults in the general population (Cerdá et al., 2012, Hasin et al., 2017, Hasin et al., 2015, Martins et al., 2016, Wall et al., 2011, Wen et al., 2015). Similarly, there has been interest in understanding whether use of medical cannabis is related to high prevalence of substance use disorders and non-cannabis substance use. For example, Grella et al. (2014) found that about half of their sample of medical cannabis users had engaged in risky alcohol use and about 20% had used illicit drugs in the past 30 days. Zaller et al. (2015) report that one-fifth of their medical cannabis patient sample reported previous treatment for drug/alcohol dependence. In contrast, several other studies have found that medical cannabis users have similar or lower rates of other drug use (Reinarman et al., 2011, Roy-Byrne et al., 2015), though relative levels of course depend on the identified comparison group and various comparison groups have been utilized in studies of medical cannabis patients (Bohnert et al., 2014, Haug et al., 2017, Ilgen et al., 2013, Lankenau et al., 2017a, Lankenau et al., 2017b). One criticism of the current literature is that studies to date have generally utilized cross sectional designs, mainly recruiting subjects from a single (e.g., Haug et al., 2017, Ilgen et al., 2013) or multiple medical cannabis dispensaries (Kepple et al., 2016, Reinarman et al., 2011), through chain referral sampling (Lankenau et al., 2017a, Lankenau et al., 2017b) or through health care settings (Davis et al., 2016, Richmond et al., 2015, Roy-Byrne et al., 2015). While some work supports that recruitment from dispensaries does not introduce substantive sampling or respondent biases (Thomas and Freisthler, 2016), others have suggested that asking medical cannabis users about other substance use in the context of recruitment at a medical cannabis assessment center might encourage under-reporting of other drug use (Reinarman et al., 2011). Concurrent assessment of other drug use after ascertainment at dispensaries might also potentially cause under-reporting because medical cannabis users are concerned with, and commonly experience, high levels of stigma (Satterlund et al., 2015). In addition, cross-section designs cannot disentangle temporal relationships (e.g., early cannabis use predicts later medical cannabis use or vice versa). One possibility that has not yet been well investigated, is that medical cannabis may serve as a convenient way for those with a cannabis addiction to access cannabis. Here we utilized a longitudinal sample, with baseline assessments in 2008 and prior years, and Wave 2 assessments in 2010–2013. We hypothesized that those with a cannabis use disorder at baseline assessment would be more likely to have a medical cannabis card at follow up. Mirroring the approach of prior studies (Grella et al., 2014, Reinarman et al., 2011), we additionally utilized Wave 2 cross-sectional data to assess whether those accessing medical cannabis have relatively high rates of concurrent substance use disorders.

One confound of testing the relationship between early cannabis use disorder and later medical cannabis use is that at baseline cannabis might have been used to mitigate general medical or mental health concerns. In other words, early health concerns might drive both early cannabis use and future medical cannabis use. There is currently moderate quality evidence supporting that cannabinoids benefit spasticity and chronic neuropathic or cancer-related pain, but evidence for other indications is of low quality (Whiting et al., 2015). One recent review also found limited evidence that cannabinoids used for medical concerns improve functioning and health-related quality of life, in part again because of limited high quality data (Goldenberg et al., 2017). The available literature on the promise of cannabinoids for various medical issues can be interpreted very differently by prominent and well-informed researchers e.g., (Haney and Evins, 2016), suggesting the importance of continued research in this area. Still, many patients use cannabis to help with various general medical and mental health concerns, including anxiety disorders, depression, and attention-deficit/hyperactivity disorder (Lucas and Walsh, 2017, Park and Wu, 2017), and report substituting medical cannabis for prescribed medications (Lucas and Walsh, 2017, Zaller et al., 2015). Although many medical cannabis users report past-year psychological distress (Grella et al., 2014) and adverse events from cannabinoids are common (McGriff et al., 2016, Whiting et al., 2015), many users also endorse subjective improvement in their symptoms from cannabis use (Grella et al., 2014, McGriff et al., 2016, Reinarman et al., 2011, Zaller et al., 2015) and report that side effects experienced are less than with prior trials of prescribed medications (Zaller et al., 2015). Thus, any study examining the longitudinal relationship between early cannabis use disorder diagnosis and later medical cannabis use, must also consider possible contributions from general medical and mental health concerns.

Section snippets

Sample

Subjects were recruited as part of a multi-site study on the genetic linkage of substance use disorders (SUDs) and conduct disorder (CD; Derringer et al., 2015). Data was collected both in Denver and San Diego and focused on adolescents, 13–19 years of age, with or at high risk for substance and conduct-related problems (hereafter referred to as probands) and their close-age siblings. In Denver, investigators recruited probands from (1) a University-based adolescent treatment program for youth

Prevalence of medical cannabis card status at Wave 2

Of the sample of 654 participants, 102 (15.6%) reported that they had obtained a medical cannabis card at Wave 2 assessment.

Bivariate analyses (Wave 1 predictors of Wave 2 medicinal card status)

Table 2 presents analyses testing whether those with and without a medical cannabis card at Wave 2 differed in Wave 1 variables. Baseline variables significantly associated with card status included: being male, race (Caucasian higher among card holders), family relationship (proband > brother > sister), several specific SUDs (cannabis, tobacco, hallucinogen, opioid and

Discussion

The study has three main findings. First, we report relatively high rates of medical cannabis card status in longitudinal follow up of a sample of high-risk adolescents and their siblings. Second, we attempted to understand what Wave 1 factors predicted Wave 2 medical cannabis card status. Our bivariate analyses identified several factors that were associated medical cannabis card status in this sample but our mulitvariate model supported that most of this predictive power is explained by

Conclusions and future directions

Adolescent cannabis abuse and dependence and male sex positively predicted future medical cannabis card holder status in this high-risk adolescent sample. Future cannabis policies should consider high-risk adolescent populations as they may be more impacted than the general population. Medical cannabis programs may also attract individuals with a history of (and concurrent) addiction to cannabis. Physicians who conduct screenings for medical cannabis recommendations have a responsibility to

Role of funding

J. Kim’s effort on this project was supported by R25DA033219. Dr. Sakai’s effort on this project was supported by DA031761; he also receives support from the Kane Family and Hewit Family Foundations. Drs. Hopfer, Corley and Young’s effort on this project was supported by 1R01 DA035804 and DA032555. Dr. Wall’s effort on this project was supported by 1R01DA035804.

Conflicts of interest

Marilyn Coors is the spouse of the Chairman of the MolsonCoorsBrewing Company, and the company has not contributed any funds nor had any influence on this project. The authors have no conflicts of interest to disclose.

Contributors

Kim contributed towards the design, analysis, data interpretation, and manuscript. Coors contributed towards the data interpretation and manuscript. Young contributed towards the analysis, data interpretation, and manuscript. Raymond contributed towards the data interpretation, and manuscript. Hopfer contributed towards the design, data interpretation, and manuscript. Wall contributed towards the data interpretation and manuscript. Corley contributed towards the data interpretation and

Acknowledgments

We thank Dr. Susan Mikulich-Gilbertson for her help in conducting the binomial regression using the generalized linear model presented in Table 3.

References (51)

  • S.E. Lankenau et al.

    Marijuana practices and patterns of use among young adult medical marijuana patients and non-patient marijuana users

    Drug Alcohol Depend.

    (2017)
  • P. Lucas et al.

    Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients

    Int. J. Drug Policy

    (2017)
  • S.S. Martins et al.

    State-level medical marijuana laws, marijuana use and perceived availability of marijuana among the general US population

    Drug Alcohol Depend.

    (2016)
  • J.L. Meyers et al.

    Genetic and environmental risk factors for adolescent-onset substance use disorders

    Child Adolesc. Psychiatr. Clin. N. Am.

    (2010)
  • J.-Y. Park et al.

    Prevalence, reasons, perceived effects, and correlates of medical marijuana use: a review

    Drug Alcohol Depend.

    (2017)
  • J. Schuermeyer et al.

    Temporal trends in marijuana attitudes, availability and use in Colorado compared to non-medical marijuana states: 2003–11

    Drug Alcohol Depend.

    (2014)
  • D. Shaffer et al.

    The diagnostic interview schedule for children-revised version (DISC-R): I. Preparation, field testing, interrater reliability, and acceptability

    J. Am. Acad. Child Adolesc. Pyschiatry

    (1993)
  • M.M. Wall et al.

    Adolescent marijuana use from 2002 to 2008: Higher in states with medical marijuana laws, cause still unclear

    Ann. Epidemiol.

    (2011)
  • Z. Walsh et al.

    Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use

    Int. J. Drug Policy

    (2013)
  • H. Wen et al.

    The effect of medical marijuana laws on adolescent and adult use of marijuana, alcohol, and other substances

    J. Health Econ.

    (2015)
  • D.W. Bowles

    Persons registered for medical marijuana in the United States

    J. Palliat. Med.

    (2012)
  • California Department of Public Health

    Card Data by County and Fiscal Year as of March 2017

    (2017)
  • California Department of Public Health

    Medical Marijuana Program Frequently Asked Questions

    (2017)
  • A. Chandran et al.

    The global burden of unintentional injuries and an agenda for progress

    Epidemiol. Rev.

    (2010)
  • Colorado Department of Public Health and Environment

    Debilitating Conditions for Medical Marijuana Use

    (2017)
  • Cited by (7)

    • Daily cannabis use, cannabis use disorder, and any medical cannabis use among US adults: Associations within racial, ethnic, and sexual minoritized identities in a changing policy context

      2022, Preventive Medicine Reports
      Citation Excerpt :

      Self-reported cannabis use for medical purposes has also increased overall, particularly in states with MCL, though the odds of cannabis use for medical purposes in Black or Hispanic adults did not appear to differ from non-Hispanic white adults (Han et al., 2018). However, some studies indicate that most people who access medical cannabis through dispensaries or report having a medical cannabis card are non-Hispanic white (Bonn-Miller et al., 2014; Kim et al., 2018). Patterns of cannabis use outcomes among sexual minoritized adults within racial and ethnic minoritized subgroups may be heterogeneous when examined by MCL status.

    • Prevalence and Correlates of Medicinal Cannabis Use Among Adolescents

      2021, Journal of Adolescent Health
      Citation Excerpt :

      The finding that MCU was associated with tobacco use, use of sedatives with a prescription, and poorer health and sleep independent from frequency of cannabis use suggests that MCU may be a unique correlate of certain types of adverse health indicators among adolescents. This finding departs from prior longitudinal U.S. studies of older adolescents, which found that only cannabis use frequency and cannabis use disorder, but not health-related variables, predicted which participants subsequently obtained a medicinal cannabis card [34,35]. Thus, it is likely that predictors of obtaining MCU authorization from a health care provider differ from predictors of self-reported MCU, as some adolescents may have non-medical motivations for obtaining MCU authorization, whereas some adolescents without authorization may still be motivated to engage in MCU to manage various symptoms.

    View all citing articles on Scopus
    View full text